SCOPUS 정보 검색 플랫폼

OncoImmunology

Volumn 2, Issue 10, 2013, Pages

Is there a future for adoptive cell transfer in melanoma patients?

(1) Besser, Michal J a,b

a SHEBA MEDICAL CENTER (Israel)

b TEL AVIV UNIVERSITY (Israel)

Author keywords

Adoptive cell transfer; Immunotherapy; Ipilimumab; Melanoma; Tumor infiltrating lymphocytes

Indexed keywords

ANTINEOPLASTIC AGENT; CD 274; IMMUNOMODULATING AGENT; INTERLEUKIN 2; IPILIMUMAB; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; VEMURAFENIB;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ARTICLE; BRAIN METASTASIS; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER REGRESSION; CANCER SURVIVAL; DRUG EFFICACY; HUMAN; LYMPHOCYTE DEPLETION; LYMPHOCYTE TRANSFER; LYMPHOCYTIC INFILTRATION; MELANOMA; METASTATIC MELANOMA; MYELOABLATIVE CONDITIONING; NONHUMAN; NONMYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; SURVIVAL RATE; SURVIVAL TIME; TUMOR ASSOCIATED LEUKOCYTE;

EID: 84890289931 PISSN: 21624011 EISSN: 2162402X Source Type: Journal
DOI: 10.4161/onci.26098 Document Type: Article

Times cited : (9)

References (10)

1
- 77951714425
- Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients
- PMID:20406835
- Besser MJ, Shapira-Frommer R, Treves AJ, Zippel D, Itzhaki O, Hershkovitz L, Levy D, Kubi A, Hovav E, Chermoshniuk N, et al. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin Cancer Res 2010; 16:2646-55; PMID:20406835; http://dx.doi.org/10.1158/1078-0432.CCR-10-0041
- (2010) Clin Cancer Res , vol.16 , pp. 2646-2655
- Besser, M.J.¹ Shapira-Frommer, R.² Treves, A.J.³ Zippel, D.⁴ Itzhaki, O.⁵ Hershkovitz, L.⁶ Levy, D.⁷ Kubi, A.⁸ Hovav, E.⁹ Chermoshniuk, N.¹⁰

2
- 55949125601
- Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens
- PMID:18809613
- Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, Robbins PF, Huang J, Citrin DE, Leitman SF, et al. Adoptive cell therapy for patients with metastatic melanoma: Evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 2008; 26:5233-9; PMID:18809613; http://dx.doi.org/10.1200/JCO.2008.16.5449
- (2008) J Clin Oncol , vol.26 , pp. 5233-5239
- Dudley, M.E.¹ Yang, J.C.² Sherry, R.³ Hughes, M.S.⁴ Royal, R.⁵ Kammula, U.⁶ Robbins, P.F.⁷ Huang, J.⁸ Citrin, D.E.⁹ Leitman, S.F.¹⁰

3
- 84887991307
- Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma
- PMID:23650429
- Dudley ME, Gross CA, Somerville RPT, Hong Y, Schaub NP, Rosati SF, White DE, Nathan D, Restifo NP, Steinberg SM, et al. Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma. J Clin Oncol 2013; 31:2152-9; PMID:23650429; http://dx.doi. org/10.1200/JCO.2012.46.6441
- (2013) J Clin Oncol , vol.31 , pp. 2152-2159
- Dudley, M.E.¹ Gross, C.A.² Somerville, R.P.T.³ Hong, Y.⁴ Schaub, N.P.⁵ Rosati, S.F.⁶ White, D.E.⁷ Nathan, D.⁸ Restifo, N.P.⁹ Steinberg, S.M.¹⁰

4
- 84871207055
- Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients
- PMID:23032743
- Radvanyi LG, Bernatchez C, Zhang M, Fox PS, Miller P, Chacon J, Wu R, Lizee G, Mahoney S, Alvarado G, et al. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res 2012; 18:6758-70; PMID:23032743; http://dx.doi.org/10.1158/1078- 0432.CCR-12-1177
- (2012) Clin Cancer Res , vol.18 , pp. 6758-6770
- Radvanyi, L.G.¹ Bernatchez, C.² Zhang, M.³ Fox, P.S.⁴ Miller, P.⁵ Chacon, J.⁶ Wu, R.⁷ Lizee, G.⁸ Mahoney, S.⁹ Alvarado, G.¹⁰

5
- 79960299888
- Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy
- PMID:21498393
- Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011; 17:4550-7; PMID:21498393; http://dx.doi.org/10.1158/1078- 0432.CCR-11-0116
- (2011) Clin Cancer Res , vol.17 , pp. 4550-4557
- Rosenberg, S.A.¹ Yang, J.C.² Sherry, R.M.³ Kammula, U.S.⁴ Hughes, M.S.⁵ Phan, G.Q.⁶ Citrin, D.E.⁷ Restifo, N.P.⁸ Robbins, P.F.⁹ Wunderlich, J.R.¹⁰

6
- 84883472041
- Adoptive Transfer of Tumor Infiltrating Lymphocytes in in Patients with Metastatic Melanoma: Intent-to-Treat Analysis and Efficacy after Failure to Prior Immunotherapies
- PMID:23690483
- Besser MJ, Shapira-Frommer R, Itzhaki O, Treves AJ, Zippel D, Levy D, Kubi A, Shoshani N, Zikich D, Ohayon Y, et al. Adoptive Transfer of Tumor Infiltrating Lymphocytes in in Patients with Metastatic Melanoma: Intent-to-Treat Analysis and Efficacy after Failure to Prior Immunotherapies. Clin Cancer Res 2013; 19:4792-800 PMID:23690483; http://dx.doi.org/10.1158/1078-0432.CCR-13-0380
- (2013) Clin Cancer Res , vol.19 , pp. 4792-4800
- Besser, M.J.¹ Shapira-Frommer, R.² Itzhaki, O.³ Treves, A.J.⁴ Zippel, D.⁵ Levy, D.⁶ Kubi, A.⁷ Shoshani, N.⁸ Zikich, D.⁹ Ohayon, Y.¹⁰

7
- 79959795786
- BRIM-3 Study Group
- PMID:21639808
- Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, et al.; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364:2507- 16; PMID:21639808; http://dx.doi.org/10.1056/NEJMoa1103782
- (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med , vol.364 , pp. 2507-2516
- Chapman, P.B.¹ Hauschild, A.² Robert, C.³ Haanen, J.B.⁴ Ascierto, P.⁵ Larkin, J.⁶ Dummer, R.⁷ Garbe, C.⁸ Testori, A.⁹ Maio, M.¹⁰

8
- 77954801079
- Improved survival with ipilimumab in patients with metastatic melanoma
- PMID:20525992
- Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466
- (2010) N Engl J Med , vol.363 , pp. 711-723
- Hodi, F.S.¹ O'Day, S.J.² McDermott, D.F.³ Weber, R.W.⁴ Sosman, J.A.⁵ Haanen, J.B.⁶ Gonzalez, R.⁷ Robert, C.⁸ Schadendorf, D.⁹ Hassel, J.C.¹⁰

9
- 79953033883
- Establishment and large-scale expansion of minimally cultured "young" tumor infiltrating lymphocytes for adoptive transfer therapy
- PMID:21304398
- Itzhaki O, Hovav E, Ziporen Y, Levy D, Kubi A, Zikich D, Hershkovitz L, Treves AJ, Shalmon B, Zippel D, et al. Establishment and large-scale expansion of minimally cultured "young" tumor infiltrating lymphocytes for adoptive transfer therapy. J Immunother 2011; 34:212-20; PMID:21304398; http://dx.doi.org/10.1097/CJI.0b013e318209c94c
- (2011) J Immunother , vol.34 , pp. 212-220
- Itzhaki, O.¹ Hovav, E.² Ziporen, Y.³ Levy, D.⁴ Kubi, A.⁵ Zikich, D.⁶ Hershkovitz, L.⁷ Treves, A.J.⁸ Shalmon, B.⁹ Zippel, D.¹⁰

10
- 84879777241
- Nivolumab plus ipilimumab in advanced melanoma
- PMID:23724867
- Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon R-A, Reed K, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369:122-33; PMID:23724867; http://dx.doi.org/10.1056/NEJMoa1302369
- (2013) N Engl J Med , vol.369 , pp. 122-133
- Wolchok, J.D.¹ Kluger, H.² Callahan, M.K.³ Postow, M.A.⁴ Rizvi, N.A.⁵ Lesokhin, A.M.⁶ Segal, N.H.⁷ Ariyan, C.E.⁸ Gordon, R.A.⁹ Reed, K.¹⁰

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.